Skip Ribbon Commands
Skip to main content

Non-Alcoholic Fatty Liver Disease Investigation Centre

Non-alcoholic fatty liver disease (NAFLD) has a high prevalence (46%) in developed countries. It is an epidemic disease and a major health issue worldwide with no FDA-approved treatments to date. The LIDPAD mouse model, which LKCMedicine has developed, is a powerful tool to study the development of non-alcoholic steatohepatitis (NASH).

n this model, NASH was induced exclusively by a dietary challenge. The LIDPAD diet does not contain any disease-causing chemicals typically used in existing models of NASH. The disease progression was characterised at several systemic, organ and molecular levels: weight gain, metabolic and behavioural dysregulations, development of glucose intolerance and insulin resistance, blood cytokine profile, histopathology, hepatic gene expression, and lipidomics. In humans, a healthy liver progresses to NASH in an ‘experimentally unrealistic’ period of many years. In the LIDPAD model, NASH develops within a few weeks and offers an opportunistic window for pharmacological interventions using drug candidates. This model will be beneficial for mechanistic and intervention studies on fatty liver, fibrosis, cirrhosis, and diabetes, among others.

The Non-Alcoholic Fatty Liver Disea
se Investigation Centre (NICE) offers this novel LIDPAD model as fee-for-service, including pharmacological and nutritional intervention studies.

For more details, please email Assoc Prof Andrew Tan​​ at and Lin Guobin at

The LIDPAD model provides a relevant and ready-to-use model to study liver disease from the healthy liver to NAFLD, NASH and fibrosis, in which disease progression is fast (less than one year to fibrosis) and triggered by diet alone, without any supplementation of chemicals. 


histopathology (Custom).png

Not sure which programme to go for? Use our programme finder
Loading header/footer ...